Determinants of RASistance to anti-epidermal growth factor receptor agents

[11] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3230 - 3237

[12] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J]. CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995

[13] Timeline - RAS oncogenes: the first 30 years [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 459 - 465

[14] KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2890 - 2896

[15] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) : 2012 - 2024

[16] Epidermal growth factor receptor targeting in cancer [J]. SEMINARS IN ONCOLOGY, 2006, 33 (04) : 369 - 385

[17] Miller VA, 2006, J CLIN ONCOL, V24, p364S

[18] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966

[19] KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J]. PLOS MEDICINE, 2005, 2 (01) : 57 - 61

[20] Philip PA, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.09.6040

[11] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3230 - 3237

[12] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J]. CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995

[13] Timeline - RAS oncogenes: the first 30 years [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 459 - 465

[14] KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2890 - 2896

[15] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) : 2012 - 2024

[16] Epidermal growth factor receptor targeting in cancer [J]. SEMINARS IN ONCOLOGY, 2006, 33 (04) : 369 - 385

[17] Miller VA, 2006, J CLIN ONCOL, V24, p364S

[18] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966

[19] KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J]. PLOS MEDICINE, 2005, 2 (01) : 57 - 61

[20] Philip PA, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.09.6040